Show
Sort by
-
- Journal Article
- A1
- open access
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer : a multicentre two-part phase I/II study
-
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refactory metastatic colorectal cancer (mCRC), treated wth irinotecan (q2w) and escalating dose of cetuximab (q1w): the EVEREST experience (preliminary data)
-
The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab
-
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
-
An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC)